跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NXSTAGE PUREFLOW SOLUTION RFP-209-CAN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NXSTAGE PUREFLOW SOLUTION RFP-209-CAN
Authorized
STANDARD
NXSTAGE PUREFLOW SOLUTION RFP-209-CAN
nxstage medical inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c170650307aab7d5
Company
nxstage medical inc
Type
Standard
Approval Details
Approval Id
c170650307aab7d5
Drug Approval Canada Name
NXSTAGE PUREFLOW SOLUTION RFP-209-CAN
Product Name
NXSTAGE PUREFLOW SOLUTION RFP-209-CAN
Status
Marketed
Status Date
2016-09-15
Original Market Date
2016-09-15
Din
02443295
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Haemodialysis
Schedule
Ethical
Ahfs
40:34.00*
Atc Original
B05ZA HEMODIALYTICS, CONCENTRATES
Atc Name
b 05 za
Aig Number
0633087010
Company Name
nxstage medical inc
Company Address
350 Merrimack Street, Lawrence, Massachusetts, United States, 01843
Active Ingredients
DEXTROSE
1.1 G / L
CALCIUM CHLORIDE
0.221 G / L
MAGNESIUM CHLORIDE
0.102 G / L
POTASSIUM CHLORIDE
0.15 G / L
SODIUM LACTATE
8.408 G / L
SODIUM CHLORIDE
5.552 G / L
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c170650307aab7d5
Type
Standard
Back to Health Canada Approvals